Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Abandoned drugs
Estradiol benzoate/estradiol phenylpropionate/testosterone propionate/testosterone phenylpropionate/testosterone isocaproate
Другие языки:

    Estradiol benzoate/estradiol phenylpropionate/testosterone propionate/testosterone phenylpropionate/testosterone isocaproate

    Подписчиков: 0, рейтинг: 0
    EB/EPP/TP/TPP/TiC
    Combination of
    Estradiol benzoate Estrogen
    Estradiol phenylpropionate Estrogen
    Testosterone propionate Androgen; Anabolic steroid
    Testosterone phenylpropionate Androgen; Anabolic steroid
    Testosterone isocaproate Androgen; Anabolic steroid
    Clinical data
    Trade names Estandron Prolongatum, Lynandron Prolongatum, Mixogen
    Other names EB/EPP/TP/TPP/TiC
    Routes of
    administration    		 Intramuscular injection
    Identifiers
    CAS Number
    PubChem CID
    ChemSpider

    Estradiol benzoate/estradiol phenylpropionate/testosterone propionate/testosterone phenylpropionate/testosterone isocaproate (EB/EPP/TP/TPP/TiC), sold under the brand names Estandron Prolongatum, Lynandron Prolongatum, and Mixogen, was an injectable combination medication of the estrogens estradiol benzoate (EB) and estradiol phenylpropionate (EPP) and the androgens/anabolic steroids testosterone propionate (TP), testosterone phenylpropionate (TPP), and testosterone isocaproate (TiC) which was used in menopausal hormone therapy for women. It was also used to suppress lactation in postpartum women.

    The medication was provided in the form of 1 mL ampoules and 2 mL vials containing 1 mg/mL EB, 4 mg/mL EPP, 20 mg/mL TP, 40 mg/mL TPP, and 40 mg/mL TiC in an oil solution and was administered by intramuscular injection. EB/EPP/TP/TPP/TiC reportedly has a duration of about 14 days.

    Estandron Prolongatum, Lynandron Prolongatum, and Mixogen were all introduced for medical use by 1956.Oral tablet products with the same brand names of Estandron, Lynandron, and Mixogen, containing ethinylestradiol and methyltestosterone, were marketed around the same time, and should not be confused with the injectable products. Estandron Prolongatum, Lynandron Prolongatum, and Mixogen remained marketed as late as the 1980s. EB/EPP/TP/TPP/TiC appears to no longer be marketed.

    Androgen replacement therapy formulations and dosages used in women
    Route Medication Major brand names Form Dosage
    Oral Testosterone undecanoate Andriol, Jatenzo Capsule 40–80 mg 1x/1–2 days
    Methyltestosterone Metandren, Estratest Tablet 0.5–10 mg/day
    Fluoxymesterone Halotestin Tablet 1–2.5 mg 1x/1–2 days
    Normethandronea Ginecoside Tablet 5 mg/day
    Tibolone Livial Tablet 1.25–2.5 mg/day
    Prasterone (DHEA)b – Tablet 10–100 mg/day
    Sublingual Methyltestosterone Metandren Tablet 0.25 mg/day
    Transdermal Testosterone Intrinsa Patch 150–300 μg/day
    AndroGel Gel, cream 1–10 mg/day
    Vaginal Prasterone (DHEA) Intrarosa Insert 6.5 mg/day
    Injection Testosterone propionatea Testoviron Oil solution 25 mg 1x/1–2 weeks
    Testosterone enanthate Delatestryl, Primodian Depot Oil solution 25–100 mg 1x/4–6 weeks
    Testosterone cypionate Depo-Testosterone, Depo-Testadiol Oil solution 25–100 mg 1x/4–6 weeks
    Testosterone isobutyratea Femandren M, Folivirin Aqueous suspension 25–50 mg 1x/4–6 weeks
    Mixed testosterone esters Climacterona Oil solution 150 mg 1x/4–8 weeks
    Omnadren, Sustanon Oil solution 50–100 mg 1x/4–6 weeks
    Nandrolone decanoate Deca-Durabolin Oil solution 25–50 mg 1x/6–12 weeks
    Prasterone enanthatea Gynodian Depot Oil solution 200 mg 1x/4–6 weeks
    Implant Testosterone Testopel Pellet 50–100 mg 1x/3–6 months
    Notes: Premenopausal women produce about 230 ± 70 μg testosterone per day (6.4 ± 2.0 mg testosterone per 4 weeks), with a range of 130 to 330 μg per day (3.6–9.2 mg per 4 weeks). Footnotes: a = Mostly discontinued or unavailable. b = Over-the-counter. Sources: See template.

    See also



    Новое сообщение